Population Pharmacokinetic-Pharmacodynamic Model of Oxfendazole in Healthy Adults in a Multiple Ascending Dose and Food Effect Study and Target Attainment Analysis-Reference-Cited by-同舟云学术

Population Pharmacokinetic-Pharmacodynamic Model of Oxfendazole in Healthy Adults in a Multiple Ascending Dose and Food Effect Study and Target Attainment Analysis

Published:2022-01-18 Issue:1 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Bach Thanh¹,Deye Gregory A.²,Codd Ellen E.³⁴,Horton John⁴⁵,Winokur Patricia⁶,An Guohua¹^ORCID

Affiliation:

1. Division of Pharmaceutics and Translational Therapeutics, College of Pharmacy, University of Iowa, Iowa City, Iowa, USA

2. Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA

3. Codd Consulting, LLC, Blue Bell, Pennsylvania, USA

4. Oxfendazole Development Group, Blue Bell, Pennsylvania, USA

5. Tropical Projects, Hitchin, United Kingdom

6. Division of Infectious Diseases, Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA

Abstract

Oxfendazole is a potent veterinary antiparasitic drug undergoing development for human use to treat multiple parasitic infections. Results from two recently completed phase I clinical trials conducted in healthy adults showed that the pharmacokinetics of oxfendazole is nonlinear, affected by food, and, after the administration of repeated doses, appeared to mildly affect hemoglobin concentrations.

Funder

Division of Intramural Research, National Institute of Allergy and Infectious Diseases

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01432-21

Reference37 articles.

1. WHO. 2020. Ending the neglect to attain the sustainable development goals–a roadmap for the neglected tropical diseases 2021–2030. https://www.who.int/neglected_diseases/Ending-the-neglect-to-attain-the-SDGs-NTD-Roadmap.pdf. Accessed 2 February 2021.

2. Albendazole therapy for neurocysticercosis: A prospective double-blind trial comparing 7 versus 14 days of treatment

3. Efficacy of recommended drugs against soil transmitted helminths: systematic review and network meta-analysis

4. Current status of diagnosis and treatment of hepatic echinococcosis

5. Filariasis: Current Status, Treatment and Recent Advances in Drug Development

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. First‐in‐human study with ACT‐1014‐6470, a novel oral complement factor 5a receptor 1 (C5aR1) antagonist, supported by pharmacokinetic predictions from animals to patients;Basic & Clinical Pharmacology & Toxicology;2022-06-08